Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

##STR00001##

A salt having formula (1) or (2) serving as an acid diffusion inhibitor is provided as well as a resist composition comprising the acid diffusion inhibitor. When processed by lithography, the resist composition exhibits a high sensitivity, and excellent lithography properties such as CDU and LWR.

##STR00001##

A quinone derivative is represented by general formula (1). In general formula (1), at least one of R.sup.1-R.sup.3 and at least one of R.sup.4-R.sup.6 each represent, independently of one another, an alkyl group having 4 to 10 carbon atoms or an alkyl group having 2 to 5 carbon atoms that has an aryl group having 6 to 14 carbon atoms. All other of R.sup.1-R.sup.3 and all other of R.sup.4-R.sup.6 each represent, independently of one another, an alkyl group having 1 to 6 carbon atoms, an aryl group having 6 to 14 carbon atoms, or a cycloalkyl group having 3 to 10 carbon atoms.

##STR00001##

The present disclosure provides an organic compound, an organic electroluminescence device and an electronic apparatus. A chemical structure of the organic compound in the present disclosure contains an adamantane spirofluorene ring and a dibenzo five-membered ring. The organic compound has an excellent energy transfer function and can be used as a luminescent layer material in an electroluminescent device, thus improving an efficiency of the organic electroluminescence device and increasing a service life of the organic electroluminescence device.

Provided herein are compounds of (I-A), (I-B), or (II), and pharmaceutically acceptable salts, solvates, hydrates, poly-morphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are methods, uses, and kits involving the inventive compounds and pharmaceutical compositions thereof for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers), inflammatory diseases (e.g., fibrosis), autoimmune diseases (e.g., sclerosis)) in a subject. Provided are methods of inhibiting the activity of a transcription factor (e.g., TEAD, such as TEAD1, TEAD2, TEAD3, TEAD4) and/or inhibiting the transcription of a gene (e.g., a gene controlled or regulated by a transcription factor (e.g., TEAD)) in a subject.

Provided are an amine compound represented by Formula 1, a light-emitting device including the same, and an electronic apparatus including the light-emitting device. The light-emitting device includes: a first electrode; a second electrode facing the second electrode; an interlayer between the first electrode and the second electrode and including an emission layer; and at least one of the amine compound represented by Formula 1.

##STR00001##

Compounds useful for treating and preventing viral infections including influenza are disclosed. Methods of treating or preventing viral infections, including influenza A infections are disclosed. Specifically, aminoadamantane derivatives that are structurally analogous to amantadine, including spirocyclic compounds, are provided for the treatment of amantadine-insensitive influenza infection in a subject.

The present specification provides a compound, a photoresist composition comprising the same, a photoresist pattern comprising the same, and a method for preparing a photoresist pattern.

The invention provides novel compounds having the general formula (I)

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as described herein, compositions including the compounds and methods of using the compounds.

Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plasma ratio of 20:1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided.